People · Operator
Named in public records as an officer, director or promoter · active 2008–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | — | Biotechnology | Series D+ | $282.2M | $940.0M | 2019 |
| Alios Biopharma Inc | — | Pharmaceuticals | Series C | $82.3M | $1.4B | 2008 |
| Alveo Technologies Inc. | — | Biotechnology | Series C | $63.6M | $503.0M | 2016 |
Lawrence Blatt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lawrence Blatt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jack Nielsen | 2 | 13 |
| Peter Hirth | 2 | 7 |
| Leonid Beigelman | 2 | 2 |
| Isaac Blech | 1 | 14 |
| Campbell Murray | 1 | 9 |
| Nicholas Brathwaite | 1 | 9 |
| Jens Eckstein | 1 | 8 |
| John Donovan | 1 | 8 |
| Peter Moldt | 1 | 6 |
| Michael Yi | 1 | 4 |
| John Fry | 1 | 4 |
| Kathleen Glaub | 1 | 3 |
| Carole Neuchterlein | 1 | 3 |
| Robin Steele | 1 | 2 |
| Kent Gossett | 1 | 2 |
| Lesley Ann Calhoun | 1 | 2 |
| Bridget Ann Martell | 1 | 2 |
| K. Peter Hirth | 1 | 2 |
| Tom Woiwode | 1 | 2 |
| Michael Aicher | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.